Semma says their tech “is the only islet cell transplantation program to have demonstrated both positive c-peptide release (a marker of insulin secretion), as well as positive glycemic control of experimentally induced diabetes.” Other than that I don’t know, other than they do look like an impressive biotech that was selected to present their proof pf concept study results during a plenary session at a major industry event. In 2017, they raised $114 million in series b financing so they had money behind them.